National Institutes of Health logo

Canine Cancer Immunotherapy Network (K9CIN; U01 Clinical Trial Not Allowed)

National Institutes of Health

Funding Amount

Not stated

Deadline

Forecast — dates not yet posted

Grant Type

Federal

Can we apply?

Check your organization against each line. Taken from the listing; confirm with the funder's guidelines.

Eligible organizations

  • Public colleges & universities
  • Public & Indian housing authorities
  • Private colleges & universities
  • Tribal organizations
  • City & township governments
  • Small businesses
  • County governments
  • School districts

Geography

  • Territory or Possession;Faith-based or Community-based Organizations;Regional Organizations;Non-domestic (non-U.S.) Entities (Foreign Institutions).

Overview

The goal of this RFA is to continue to support canine cancer immunotherapy clinical trials as indicators of safe and effective cancer treatments in humans. Pet dog patients develop cancer spontaneously and the courses of disease and treatment responses are similar to those in humans. Canine clinical trial results are translatable to humans. The assessment of responses to immunotherapy in immune-intact animals with existing cancers, such as pet dog patients, is the only way to preclinically take into account all facets of the immune response to cancer and to therapies. Ethically, pet dogs can benefit from the clinical trials by receiving cutting-edge therapies supported by the NIH, while providing important data informative to human disease. The network supported by this U01 RFA will consist of five U01 awards. One U01 will serve as a multifunctional Network Coordinating Center that will not only facilitate coordination across the Canine Cancer Immunotherapy Network (K9CIN) but will also perform limited research to support the network. Four U01 recipients will conduct canine clinical trials using immunotherapeutic agents alone or in combination with other treatment modalities. Through this reissue Notice of Funding Opportunity, the National Cancer Institute intends to continue to support canine immunotherapeutic development as the field continues to grow, in part because of NIH funding. In the last five years, canine immunotherapeutics such as immune checkpoint inhibitors have become available as have canine analytics, development of which were partially supported by NCI. The goal is to maintain the momentum for further development of canine analytics and therapeutics and the ability to evaluate novel and repurposed drugs, treatment combinations, and treatment dosing and sequencing in pet dogs in a timely fashion. This NOFO consolidates the prior U01 (RFA-CA-21-050) and U24 (RFA-CA-21-051) funding opportunities to streamline the application process for continued supp

Details

  • Agency: National Institutes of Health
  • Department: Department of Health and Human Services
  • Opportunity #: RFA-CA-26-010
  • Instrument: cooperative_agreement

Eligibility

Other Eligible ApplicantsIndian/Native American Tribal Governments (Other than Federally Recognized);Eligible Agencies of the Federal Government;U.S. Territory or Possession;Faith-based or Community-based Organizations;Regional Organizations;Non-domestic (non-U.S.) Entities (Foreign Institutions).

Focus Areas & Funding Uses

Fields of Work

  • Cancer
  • Science research

Categories

Browse similar grants by category

Related Grants

Open grants from this funder and similar programs

Your AI grants department

Ready to apply for Canine Cancer Immunotherapy Network (K9CIN; U01 Clinical Trial Not Allowed)?

Grantable helps you assess fit, draft narratives, and track deadlines — so you can submit stronger applications, faster.

You found Canine Cancer Immunotherapy Network (K9CIN; U01 Clinical Trial Not Allowed). Now let's win it.

Start writing